Asst prof @UChicagoMed. Focus on melanoma and cancer immunotherapy // @rushumedcollege @NU_IntMed @UCHemOncFellows alum.
Chicago, IL
Joined October 2013
- Tweets97
- Following706
- Followers480
- Likes665
Excellent insights from @JohnEMullinaxMD and Dr. Lauren Banks on the emerging efficacy of TIL in sarcoma. Thanks for @ASTCT for the opportunity to host these experts. @UChicagoHemOnc @UCCancerCenter
Can TIL therapy become a new treatment option for patients with sarcoma?
In this episode of ASTCT Talks, host Daniel Olson, MD, is joined by John Mullinax, MD, and Lauren Banks, MD, PhD, to discuss the emerging role of tumor-infiltrating lymphocyte (TIL) therapy in sarcoma. The conversation explores early clinical results, patient selection, tumor procurement, and the multidisciplinary collaboration needed to bring this promising cellular therapy approach to patients with solid tumors.
🎧 Listen now: ow.ly/7Tqn50ZWQTc
Two recent projects focused on TIL therapy:
🎙️ A convo with TIL experts for ASTCT Talks @DrBetofMDPhD @slgoff_SB @ASTCT
📄 Our new review in Cancer on the history and future of TIL therapy @UCCancerCenter
Podcast: open.spotify.com/episode/5lA…
Paper: acsjournals.onlinelibrary.wi…
Dan Olson retweeted
New #OpenAccess review article from @DanielOlsonMD et al on tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions
acsjournals.onlinelibrary.wi…
@OncoAlert @AlexandraRojek CC: @diwakardavar
New @JCOOP_ASCO analysis from NCI/SWOG S1404 adds important rigor to the debate over time-of-day immunotherapy infusions. After accounting for bias/confounding, pembrolizumab infusion timing was not robustly associated with efficacy outcomes.
ascopubs.org/doi/10.1200/OP-…
Our accompanying editorial highlights the strengths of this work among the ongoing debate in the field and the recent retraction of a high-profile chrono-immunotherapy paper.
ascopubs.org/doi/10.1200/OP-…
@UCCancerCenter @UChicagoHemOnc
Lots of promise with TIL, and hope it can expand outside of melanoma, but have to make next generations easier to scale.
Thanks @DrKedarKirtane , @DrFredLocke and @MoffittNews for having me.
From #CellCoast25: Dan Olson, MD (@DanielOlsonMD) of @UChicago reviews data leading to the FDA approval of lifileucel and explores future directions for TIL therapy across solid tumors.
Key Takeaways:
➡️ Lifileucel shows strong activity in PD-1–refractory melanoma.
➡️ IL-2 analogs and modified lymphodepletion may enhance safety and efficacy.
➡️ Advances in TIL manufacturing (neoantigen and phenotype selection, cytokine engineering) show promise but face scalability challenges.
It's always wonderful to reflect and to celebrate the wins with your patients, but I'm particularly grateful for this one: my sister-in-law Jenn's story of being cancer free 10 years out from stage IV NSCLC. #Immunotherapy
patientpower.info/lung-cance…
We are grateful to offer TIL to patients in need. The behind-the-scenes efforts for all involved teams is immense. However, the stress fades easily when the results shine like this.
uchicagomedicine.org/forefro…
Dan Olson retweeted
Story comes around 360 with my fellow @sitcancer #Sparkathon2018 classmate @DanielOlsonMD sharing the @ASCO Developmental Therapeutics IO session together today!! Also awesome cochair @TiansterZhang and other speakers @APConley77 @DrVaishampayan and others !
Dan Olson retweeted
📢 Exciting news: The University of Chicago Medicine is among the first 30 institutions in the country to offer tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma. #BreakThroughTherapy
@UChicagoMed @UCCancerCenter @UChicagoHemOnc
ow.ly/1J1R50QFMJN
Wonderful news and I couldn't agree more. This is great news for our patients with advanced melanoma. Looking forward to offering this at U Chicago! @UCCancerCenter
Lifileucel (TIL cell therapy from @IovanceBio) is now FDA approved for advanced PD-1 refractory melanoma!!! The melanoma community is so grateful to the patients, caregivers, and clinicians who have made the clinical trials of this therapy possible and got lifileucel to approval. We are very excited to bring this life-saving therapy to patients ASAP! Available immediately at @StanfordCancer!!!
ir.iovance.com/news-releases…
“Everything about TILs is a pain in the neck,” says Nick Restifo,... “There's only one saving grace, and that is that they work.”
This is an insightful history of TIL as we're on the cusp of this therapy coming available for patients with melanoma.
nature.com/articles/d41573-0….
Neoadjuvant immunotherapy for resectable melanoma carries huge promise to personalize treatment and improve outcomes, but randomized data is only now emerging. I reviewed the current studies and trade-offs of PD-1 Abs vs ipi combos. #ASCODailyNews @ASCO
dailynews.ascopubs.org/do/we…
Cell therapy for solid tumors: progress, promise, and much to come. Here is a review by @KunleOdunsiMD and me on the current state of the field, its challenges, and way to expand efficacy. @UChicagoHemOnc @JCO_ASCO
ascopubs.org/doi/abs/10.1200…
TIL therapy is looking like a great option for some after PD-1 Abs fail in advanced melanoma. It will be interesting to see how and when we can use this for patients, and where we ultimately use ipi.
nejm.org/doi/full/10.1056/NE…
Congrats to @DrRobinReschke and team for making this project a reality!
We questioned if tissue-resident memory (Trm) T cells played a role in immune-related adverse events. As nicely shown here, they do expand after checkpoint inhibition in these irAE cases.
📢 New publication alert 📢 please check out and share our new paper about the relevance of tissue resident memory T cells in IO toxicity of barrier organs🚨 It is still free to download in the “online-first” version!😉 @DanielOlsonMD @jovianyu @srouhani1
aacrjournals.org/cancerimmun…
Props to @srouhani1 for leading this project confirming COVID-19 vaccinations are safe and effective in pt's receiving immuno and chemotherapies; lower titers in patients receiving B-cell directed therapies.
And watch your patients with adrenal insufficiency closely!
New #JITC article: Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies bit.ly/3NrngCZ @srouhani1 @jovianyu @DanielOlsonMD @bdermanmd
Dan Olson retweeted
A groundbreaking cancer drug has been helping UChicago Medicine patients for years in clinical trials. In January, the FDA approved the drug, which treats uveal melanoma. ms.spr.ly/6018wfbri